Edesa Biotech Total Assets Growth & History (EDSA)
Edesa Biotech's total assets was $13.5M for fiscal 2025.
View full Edesa Biotech company overviewEdesa Biotech annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-09-30 | $13.5M | $9.7M | +254.76% |
| 2024 | 2024-09-30 | $3.8M | −$5.1M | −57.10% |
| 2023 | 2023-09-30 | $8.9M | −$2.7M | −23.20% |
| 2022 | 2022-09-30 | $11.6M | −$3.0M | −20.63% |
| 2021 | 2021-09-30 | $14.6M | $3.8M | +35.52% |
| 2020 | 2020-09-30 | $10.8M | $5.0M | +88.23% |
| 2019 | 2019-09-30 | $5.7M | −$6.1M | −51.46% |
| 2018 · Dec 31 | 2018-12-31 | $3.4M | — | — |
| 2018 · Sep 30 | 2018-09-30 | $11.8M | $4.1M | +52.59% |
| 2017 | 2017-09-30 | $7.7M | −$5.2M | −40.33% |
| 2016 | 2016-09-30 | $12.9M | $2.6M | +24.57% |
| 2015 | 2015-09-30 | $10.4M | — | — |
| 2014 | 2014-08-31 | $14.5M | $6.0M | +70.01% |
| 2013 | 2013-08-31 | $8.5M | — | — |
Edesa Biotech quarterly total assets
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q3 2026 | 2026-06-30 | $12.7M | −$2.1M | −14.07% |
| Q2 2026 | 2026-03-31 | $12.4M | −$4.1M | −24.73% |
| Q1 2026 | 2025-12-31 | $14.7M | $10.5M | +253.26% |
| Q4 2025 | 2025-09-30 | $13.5M | $9.7M | +254.76% |
| Q3 2025 | 2025-06-30 | $14.8M | $9.6M | +183.20% |
| Q2 2025 | 2025-03-31 | $16.5M | $10.0M | +154.12% |
| Q1 2025 | 2024-12-31 | $4.2M | −$3.7M | −46.83% |
| Q4 2024 | 2024-09-30 | $3.8M | −$5.1M | −57.10% |
| Q3 2024 | 2024-06-30 | $5.2M | −$4.2M | −44.50% |
| Q2 2024 | 2024-03-31 | $6.5M | −$4.2M | −39.34% |
| Q1 2024 | 2023-12-31 | $7.8M | −$3.8M | −32.92% |
| Q4 2023 | 2023-09-30 | $8.9M | −$2.7M | −23.20% |
| Q3 2023 | 2023-06-30 | $9.4M | −$8.1M | −46.30% |
| Q2 2023 | 2023-03-31 | $10.7M | −$9.7M | −47.70% |
| Q1 2023 | 2022-12-31 | $11.7M | −$668,594 | −5.42% |
| Q4 2022 | 2022-09-30 | $11.6M | −$3.0M | −20.63% |
| Q3 2022 | 2022-06-30 | $17.5M | $663,858 | +3.93% |
| Q2 2022 | 2022-03-31 | $20.4M | −$3.6M | −14.97% |
| Q1 2022 | 2021-12-31 | $12.3M | $2.1M | +19.95% |
| Q4 2021 | 2021-09-30 | $14.6M | $3.8M | +35.52% |
| Q3 2021 | 2021-06-30 | $16.9M | $8.0M | +89.15% |
| Q2 2021 | 2021-03-31 | $24.0M | $16.4M | +214.46% |
| Q1 2021 | 2020-12-31 | $10.3M | $5.2M | +102.20% |
| Q4 2020 | 2020-09-30 | $10.8M | $5.0M | +88.23% |
| Q3 2020 | 2020-06-30 | $8.9M | $1.7M | +23.45% |
| Q2 2020 | 2020-03-31 | $7.6M | −$1.5M | −16.59% |
| Q1 2020 | 2019-12-31 | $5.1M | $1.7M | +49.76% |
| Q4 2019 | 2019-09-30 | $5.7M | −$6.1M | −51.46% |
| Q2 2019 | 2019-06-30 | $7.2M | −$5.6M | −43.54% |
| Q1 2019 | 2019-03-31 | $9.2M | $3.8M | +71.70% |
| Q4 2018 · Dec 31 | 2018-12-31 | $3.4M | −$3.2M | −48.46% |
| Q4 2018 · Sep 30 | 2018-09-30 | $11.8M | $4.1M | +52.59% |
| Q3 2018 | 2018-06-30 | $12.8M | $3.8M | +41.89% |
| Q2 2018 | 2018-03-31 | $5.3M | −$4.9M | −47.87% |
| Q1 2018 | 2017-12-31 | $6.6M | −$4.9M | −42.50% |
| Q4 2017 | 2017-09-30 | $7.7M | −$5.2M | −40.33% |
| Q3 2017 | 2017-06-30 | $9.0M | $522,254 | +6.14% |
| Q2 2017 | 2017-03-31 | $10.2M | $794,251 | +8.42% |
| Q1 2017 | 2016-12-31 | $11.5M | $1.1M | +10.74% |
| Q4 2016 | 2016-09-30 | $12.9M | $2.6M | +24.57% |
| Q3 2016 | 2016-06-30 | $8.5M | −$2.7M | −24.20% |
| Q2 2016 | 2016-03-31 | $9.4M | −$2.4M | −20.28% |
| Q1 2016 | 2015-12-31 | $10.4M | −$3.1M | −22.88% |
| Q4 2015 | 2015-09-30 | $10.4M | — | — |
| Q3 2015 | 2015-06-30 | $11.2M | — | — |
| Q2 2015 | 2015-03-31 | $11.8M | — | — |
| Q1 2015 | 2014-12-31 | $13.4M | — | — |
| Q4 2014 | 2014-08-31 | $14.5M | — | — |
Edesa Biotech total assets trends
Over the last five fiscal years, Edesa Biotech's total assets increased from $10.8M to $13.5M, a change of $2.8M. The latest reported quarter, Q3 2026, shows $12.7M.
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Edesa Biotech source filings ↗